The Project HERCULES Steering Group is the decision-making body which oversees the delivery of the objectives of Project HERCULES. The group meets twice a year and is chaired by Fleur Chandler.

Access to Project HERCULES Steering Group content is restricted to Steering Group members only.

Project HERCULES team

Members include:

• Fleur Chandler (Chair), Duchenne UK and Sanofi UK
• Emily Reuben, Duchenne UK
• Josie Godfrey, JG Zebra Consulting

Companies

Members include representatives from:

• Astellas Pharma Inc
• Catabasis Pharmaceuticals Inc
• Pfizer Inc
• PTC Therapeutics International Limited,
• Roche
• Sarepta Therapeutics Inc
• Solid Biosciences LLC
• Santhera Pharmaceuticals Holding AG
• Wave Life Sciences USA

Patient groups

Members include representatives from:

• PPMD (US)
• World Duchenne Organisation (UPPMD)
• Save Our Sons (Australia)
• Stand For Duchenne Canada
• Jesse’s Journey (Canada)

Advisers

• Prof Ron Akehurst, BresMed
• Meriem Bouslouk, Independent German HTA expert
• Merce Obach Cortadellas, Catsalut
• Prof Jalpa Doshi, University of Pennsylvania
• Karen Facey, University of Edinburgh
• Dr Michela Guglieri, Newcastle University
• Anthony Hatswell, Delta Hat
• Jane Larkindale, C-Path (US)
• Dr Anna Sarkozy, GOSH London
• Juliana Setyawan, US
• James Signorovitch and Susan Ward, cTAP (US)  
• Ian Watson, NICE  
• Dr Jarod Wong, University of Glasgow

Vendors

Vendors also attend the Steering Group:

• Aparito
• HCD Economics
• Oxford University Innovation
• Pharmatelligence
• Sheffield School of Health and Related Research (ScHARR)
• Source HEOR
• Tolley Health Economics
• University of Leicester